Health Care • Biotechnology: Laboratory Analytical Instruments
$0.79 ▼ -0.01
(-1.37%)
MKT CAP: $39.6M • VOL: 192.2K
52W L $1 52W H $5
ROARABLE / RQD
D • 47/100
PIOTROSKI
4 / 9
RPID // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $33.6M | $28.1M | $22.5M |
| YoY Revenue Growth % | +19.7% | +24.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$47.4M | -$49.9M | -$56.6M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$47.1M | -$46.9M | -$52.5M |
| EBITDA (Normalized) | -$46.7M | -$48.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$31.1M | -$44.2M | -$45.1M |
| Capital Expenditures (CapEx) | $850.0K | $1.4M | — |
| Free Cash Flow (FCF) | -$31.9M | -$45.5M | -$45.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $20.0M | $16.9M | — |
| Total Debt (Short + Long Term) | $18.9M | $0 | — |
| Total Stockholders' Equity | $33.2M | $75.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RPID.